Daniel R. Tereau net worth and biography

Daniel Tereau Biography and Net Worth

Insider of Revvity

Mr. Tereau joined PerkinElmer in April 2014 as Vice President, Strategy and Business Development and was appointed Senior Vice President in January 2016. He is responsible for leading PerkinElmer’s overall strategic planning, business development, and corporate marketing activities.

Prior to joining PerkinElmer, Mr. Tereau served on Novartis’ leadership team as Senior Vice President and Global Head of Strategy, Business Development and Licensing, where he was responsible for global strategy and business development for the Consumer Health division. Prior to that, he held similar roles at GE Healthcare and Thermo Fisher Scientific.

Mr. Tereau holds a Bachelor of Science degree in Finance from Ferris State University, a Juris Doctor degree from Wayne State University, and a Master of Business Administration degree from Yale University. He also serves on the Board of Directors for SeraCare Life Sciences.

What is Daniel R. Tereau's net worth?: The estimated net worth of Daniel R. Tereau is at least $0.00 as of March 20th, 2023. Mr. Tereau owns 11,611 shares of Revvity stock worth more than $0 as of March 27th. This net worth estimate does not reflect any other assets that Mr. Tereau may own. Learn More about Daniel R. Tereau's net worth.
How do I contact Daniel R. Tereau?: The corporate mailing address for Mr. Tereau and other Revvity executives is 940 WINTER STREET, WALTHAM MA, 02451. Revvity can also be reached via phone at (781) 663-6900 and via email at ir@perkinelmer.com. Learn More on Daniel R. Tereau's contact information.
Has Daniel R. Tereau been buying or selling shares of Revvity?: Daniel R. Tereau has not been actively trading shares of Revvity within the last three months. Most recently, Daniel R. Tereau sold 10,741 shares of the business's stock in a transaction on Monday, March 20th. The shares were sold at an average price of $123.72, for a transaction totalling $1,328,876.52. Following the completion of the sale, the insider now directly owns 11,611 shares of the company's stock, valued at $1,436,512.92. Learn More on Daniel R. Tereau's trading history.
Who are Revvity's active insiders?: Revvity's insider roster includes Peter Barrett (Director), Joel Goldberg (Insider), Sylvie Gregoire (Director), Maxwell Krakowiak (Insider), James Mock (Insider), Andrew Okun (Insider), Prahlad Singh (Insider), Daniel Tereau (Insider), and Tajinder Vohra (Insider). Learn More on Revvity's active insiders.

Daniel R. Tereau Insider Trading History at Revvity

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2023	Sell	10,741	$123.72	$1,328,876.52	11,611
7/22/2022	Sell	5,700	$145.14	$827,298.00	13,380
3/14/2022	Sell	6,696	$165.84	$1,110,464.64
12/9/2021	Sell	3,546	$189.55	$672,144.30
2/1/2021	Sell	2,047	$147.07	$301,052.29	10,378
12/14/2020	Sell	4,094	$146.68	$600,507.92
6/15/2020	Sell	5,452	$95.22	$519,139.44
3/7/2019	Sell	1,200	$93.27	$111,924.00	5,839
9/24/2018	Sell	3,308	$96.58	$319,486.64	10,092
4/18/2018	Sell	1,156	$77.00	$89,012.00	6,784
2/9/2017	Sell	5,001	$53.16	$265,853.16	12,147
2/6/2017	Sell	4,069	$52.01	$211,628.69	9,465
9/12/2016	Sell	18,866	$52.00	$981,032.00	21,241
4/18/2016	Sell	2,158	$50.79	$109,604.82	8,602

Daniel R. Tereau Buying and Selling Activity at Revvity

Revvity Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Today's Range

Now: N/A

50 Day Range

MA: $127.73

$115.24

$137.11

2 Week Range

Now: N/A

Volume

1,633,000 shs

Average Volume

851,117 shs

Market Capitalization

$14.57 billion

P/E Ratio

15.01

Dividend Yield

0.24%

Beta

1.1